Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241577 | 0.87 | LIPG (0.42) | CTSLCTSBCTSKLPLLIPG | |
| SCHEMBL19023658 | 0.82 | LPL (0.39) | CTSLCTSBCTSKLPLLIPG | |
| SCHEMBL25339093 | 0.82 | CTSL (0.31) | CTSLCTSBCTSK | |
| SCHEMBL26092099 | 0.76 | — | — | |
| SCHEMBL20303253 | 0.76 | CTSL (0.42) | CTSLCTSBCTSKLPLLIPG | |
| SCHEMBL17220074 | 0.76 | GPR119 (0.38) | CTSLCTSBCTSKSLC1A3SLC1A2 | |
| SCHEMBL30395803 | 0.75 | PDK2 (0.36) | — | |
| SCHEMBL22464956 | 0.74 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL6134660 | 0.74 | CTSL (0.45) | CTSLCTSBCTSKSLC1A3SLC1A2 | |
| SCHEMBL25366541 | 0.74 | LPL (0.32) | CTSLCTSBCTSKLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-3341379-B1 | INHIBITORS OF EZH2 | LILLY CO ELI (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3341379-A1 | INHIBITORS OF EZH2 | Eli Lilly and Company (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9718838-B2 | Inhibitors of EZH2 | ELI LILLY AND COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170066780-A1 | INHIBITORS OF EZH2 | ELI LILLY AND COMPANY | 2017-03-09 | — | — | US | disclosed |
| WO-2017035060-A1 | INHIBITORS OF EZH2 | ELI LILLY AND COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066780-A1 | INHIBITORS OF EZH2 | EZH2, BMI1, EZH1 | CTSL 4116/4885CTSB 2748/4885CTSK 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.